Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8082)	3/27/2003 4:07:15 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

I thought I should discuss what's been happening with my overall portfolio, as there have been some fairly dramatic changes. Most of the change has been near the top - SCIO of course is effectively gone because of the merger, ITMN is virtually gone although I did re-enter with a small position a month or so ago, and IGEN is much reduced - I have only about 20% of my original significant position. The only significant purchase I have made has been GILD - I exercised some of the March 35 options I had bought, and as a result it has become my third biggest position (ignoring SCIO). So my positions in order are as follows: SEPR (biggest by a lot) SCIO (essentially cash) FRX GILD NBIX IGEN (reduced significantly at higher levels) KDUS CELG KOSP KOSN MOGN NTII (sold part at higher levels) CNCT REGN With the exception of KOSN they have generally been doing fairly well this year, considering the overall environment. Overall I have moved to a more conservative posture, with smaller long positions and more hedging of the overall market. Peter

To: Biomaven who wrote (8082)	3/27/2003 4:08:50 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Peter Thanks. I had hoped for some background information on ArthroCare. Artimplant are closing a rights' issue tomorrow. The share is now trading below the issue price. So, today's announcement should boost their chances to bring home some fresh funds. The thing is further complicated by the fact that Artimplant's CEO sits on ArthroCare's board. So the whole set-up including the six-month marketing "try as you sell" arrangement is a little bit "unconventional". I am trying to figure out how (if?) serious ArthroCare are. Erik